Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis

Background: Immune checkpoint inhibitors (ICIs) are employed to treat various cancers, including soft tissue sarcomas (STSs), and less than 20% of patients benefit from this treatment. Vascular endothelial growth factor (VEGF) promotes the immunosuppressive tumor microenvironment and contributes to...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Yang, Guo, Xi, Zhuang, Rongyuan, Zhang, Chenlu, Wang, Zhiming, Shen, Feng, Wang, Yan, Liu, Wenshuai, Zhang, Yong, Lu, Weiqi, Hou, Yingyong, Wang, Jing, Zhang, Xuan, Lu, Minzhi, Zhou, Yuhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635153/
https://www.ncbi.nlm.nih.gov/pubmed/34869583
http://dx.doi.org/10.3389/fmolb.2021.747650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635153/
https://www.ncbi.nlm.nih.gov/pubmed/34869583
http://dx.doi.org/10.3389/fmolb.2021.747650

Ejemplares similares